November 05, 2015.
Janssen has reported that it is "extremely pleased" that NHS England confirmed that its drug ibrutinib (Imbruvica) will remain on the Cancer Drugs Fund (CDF) for the treatment of two types of blood cancer, chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). This follows news September 4 that had identified ibrutinib for potential de-listing.
Ibrutinib is a member of a new class of targeted medicines and was granted a licence based on trial data from two separate studies. The treatment can now continue to benefit eligible UK patients with relapsed or refractory CLL and MCL whose disease has come back following their first treatment.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.